Cancer‐specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy
Objective This study aimed to assess survival outcomes in older patients with de novo metastatic prostate cancer who initially received androgen deprivation therapy. Methods The retrospective multicenter study included 2784 men with metastatic prostate cancer who were treated with androgen deprivati...
Gespeichert in:
| Veröffentlicht in: | International journal of urology 2022-10, Vol.29 (10), p.1147-1154 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1154 |
|---|---|
| container_issue | 10 |
| container_start_page | 1147 |
| container_title | International journal of urology |
| container_volume | 29 |
| creator | Narita, Shintaro Terada, Naoki Nomura, Kyoko Sakamoto, Shinichi Hatakeyama, Shingo Kato, Takuma Matsui, Yoshiyuki Inokuchi, Junichi Yokomizo, Akira Tabata, Ken‐ichi Shiota, Masaki Kimura, Takahiro Kojima, Takahiro Inoue, Takahiro Mizowaki, Takashi Sugimoto, Mikio Kitamura, Hiroshi Kamoto, Toshiyuki Nishiyama, Hiroyuki Habuchi, Tomonori Saito, Toshihiro Yoshimura, Koji Takahashi, Atsushi Shimazui, Toru Goto, Takayuki Hashimoto, Yasuhiro Nagumo, Yoshiyuki Yasumoto, Hiroaki Mitsuzuka, Koji Ito, Akihiro Matsumoto, Hiroaki Sugiyama, Takayuki Miyake, Hideaki Kuroiwa, Kentaro Tsuchiya, Norihiko Fukuta, Fumimasa Morizane, Shuichi Sato, Hiromi Saito, Takuro Shinohara, Nobuo Enokida, Hideki Yonemori, Masaya |
| description | Objective
This study aimed to assess survival outcomes in older patients with de novo metastatic prostate cancer who initially received androgen deprivation therapy.
Methods
The retrospective multicenter study included 2784 men with metastatic prostate cancer who were treated with androgen deprivation therapy between 2008 and 2017. Patients were classified into |
| doi_str_mv | 10.1111/iju.14938 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2670062123</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2722364281</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3378-2dbd14869b905566675ebd48b9dc7d2f3650e26585b3619f94669d7d80d7ad393</originalsourceid><addsrcrecordid>eNp1kc1u1DAUhS0EokNhwQsgS2xgkdY_iRMv0Yifokps6Npy4hvqUcYOtjPV7PoILHk-noTbprBAwhtb9nfPub6HkJecnXFc5363nPFay-4R2fC6FpVgtXhMNkxzXXW8FSfkWc47xrgUvHtKTmSjuNRSbcjPrQ0DpF-3P_IMgx_9QG1wNECh8QDJThPNSzr4g52oDzRODhKdbfEQSqY3vlxTBzTEQ6R7KDYXfBronOLdCehwr46VvnjUOtKSAO_dWolOKX6DgBJzQoviY6DlGm3n43PyZLRThhcP-ym5-vD-6_ZTdfnl48X23WU1SNl2lXC943WndK9Z0yil2gZ6V3e9dkPrxChVw0Copmt6qbgeda2Udq3rmGutwxmckjerLvb8fYFczN7nAabJBohLNkK1jCnBhUT09T_oLi4pYHdGtEJIVYuOI_V2pQYcQk4wGvzb3qaj4czcxWUwLnMfF7KvHhSXfg_uL_knHwTOV-DGT3D8v5K5-Hy1Sv4GKtmiUA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2722364281</pqid></control><display><type>article</type><title>Cancer‐specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy</title><source>Wiley-Blackwell Journals</source><creator>Narita, Shintaro ; Terada, Naoki ; Nomura, Kyoko ; Sakamoto, Shinichi ; Hatakeyama, Shingo ; Kato, Takuma ; Matsui, Yoshiyuki ; Inokuchi, Junichi ; Yokomizo, Akira ; Tabata, Ken‐ichi ; Shiota, Masaki ; Kimura, Takahiro ; Kojima, Takahiro ; Inoue, Takahiro ; Mizowaki, Takashi ; Sugimoto, Mikio ; Kitamura, Hiroshi ; Kamoto, Toshiyuki ; Nishiyama, Hiroyuki ; Habuchi, Tomonori ; Saito, Toshihiro ; Yoshimura, Koji ; Takahashi, Atsushi ; Shimazui, Toru ; Goto, Takayuki ; Hashimoto, Yasuhiro ; Nagumo, Yoshiyuki ; Yasumoto, Hiroaki ; Mitsuzuka, Koji ; Ito, Akihiro ; Matsumoto, Hiroaki ; Sugiyama, Takayuki ; Miyake, Hideaki ; Kuroiwa, Kentaro ; Tsuchiya, Norihiko ; Fukuta, Fumimasa ; Morizane, Shuichi ; Sato, Hiromi ; Saito, Takuro ; Shinohara, Nobuo ; Enokida, Hideki ; Yonemori, Masaya</creator><creatorcontrib>Narita, Shintaro ; Terada, Naoki ; Nomura, Kyoko ; Sakamoto, Shinichi ; Hatakeyama, Shingo ; Kato, Takuma ; Matsui, Yoshiyuki ; Inokuchi, Junichi ; Yokomizo, Akira ; Tabata, Ken‐ichi ; Shiota, Masaki ; Kimura, Takahiro ; Kojima, Takahiro ; Inoue, Takahiro ; Mizowaki, Takashi ; Sugimoto, Mikio ; Kitamura, Hiroshi ; Kamoto, Toshiyuki ; Nishiyama, Hiroyuki ; Habuchi, Tomonori ; Saito, Toshihiro ; Yoshimura, Koji ; Takahashi, Atsushi ; Shimazui, Toru ; Goto, Takayuki ; Hashimoto, Yasuhiro ; Nagumo, Yoshiyuki ; Yasumoto, Hiroaki ; Mitsuzuka, Koji ; Ito, Akihiro ; Matsumoto, Hiroaki ; Sugiyama, Takayuki ; Miyake, Hideaki ; Kuroiwa, Kentaro ; Tsuchiya, Norihiko ; Fukuta, Fumimasa ; Morizane, Shuichi ; Sato, Hiromi ; Saito, Takuro ; Shinohara, Nobuo ; Enokida, Hideki ; Yonemori, Masaya ; Japanese Urological Oncology Group ; the Japanese Urological Oncology Group</creatorcontrib><description>Objective
This study aimed to assess survival outcomes in older patients with de novo metastatic prostate cancer who initially received androgen deprivation therapy.
Methods
The retrospective multicenter study included 2784 men with metastatic prostate cancer who were treated with androgen deprivation therapy between 2008 and 2017. Patients were classified into <75, 75–79, and ≥80 age groups. Propensity score matching was conducted to assess the cancer‐specific survival of the groups. The 5‐year net overall survival of each group was derived to evaluate relative survival compared with the general population using the Pohar–Perme estimator and the 2019 Japan Life Table.
Results
During the follow‐up (median, 34 months), 1014 patients died, of which 807 died from metastatic prostate cancer progression. Compared with the <75 group, the cancer‐specific survival of the 75–79 group was similar (hazard ratio 1.07; 95% confidence interval 0.84–1.37; P = 0.580), whereas that of the ≥80 group was significantly worse (hazard ratio 1.41; 95% confidence interval 1.10–1.80; P = 0.006). The 5‐year net overall survival of the <75, 75–79, and ≥80 age groups were 0.678, 0761, and 0.718, respectively. The 5‐year net overall survival of patients aged ≥80 years with low‐ and high‐volume disease were 0.893 and 0.586, respectively, which was comparable with those in patients aged <75 years (0.872 and 0.586, respectively).
Conclusions
Older metastatic prostate cancer patients aged ≥80 years had poorer cancer‐specific survival compared with younger patients. Conversely, 5‐year net overall survival in older patients aged ≥80 years was comparable with that in younger patients aged <75 years.</description><identifier>ISSN: 0919-8172</identifier><identifier>EISSN: 1442-2042</identifier><identifier>DOI: 10.1111/iju.14938</identifier><identifier>PMID: 35613936</identifier><language>eng</language><publisher>Australia: Wiley Subscription Services, Inc</publisher><subject>Age groups ; androgen deprivation therapy ; Androgens ; cancer‐specific survival ; Confidence intervals ; Metastases ; Metastasis ; metastatic ; older ; Prostate cancer ; Survival</subject><ispartof>International journal of urology, 2022-10, Vol.29 (10), p.1147-1154</ispartof><rights>2022 The Japanese Urological Association.</rights><rights>2022 The Japanese Urological Association</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3378-2dbd14869b905566675ebd48b9dc7d2f3650e26585b3619f94669d7d80d7ad393</cites><orcidid>0000-0002-5673-1553 ; 0000-0001-8586-784X ; 0000-0002-8135-8746 ; 0000-0003-2988-1860</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fiju.14938$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fiju.14938$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35613936$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Narita, Shintaro</creatorcontrib><creatorcontrib>Terada, Naoki</creatorcontrib><creatorcontrib>Nomura, Kyoko</creatorcontrib><creatorcontrib>Sakamoto, Shinichi</creatorcontrib><creatorcontrib>Hatakeyama, Shingo</creatorcontrib><creatorcontrib>Kato, Takuma</creatorcontrib><creatorcontrib>Matsui, Yoshiyuki</creatorcontrib><creatorcontrib>Inokuchi, Junichi</creatorcontrib><creatorcontrib>Yokomizo, Akira</creatorcontrib><creatorcontrib>Tabata, Ken‐ichi</creatorcontrib><creatorcontrib>Shiota, Masaki</creatorcontrib><creatorcontrib>Kimura, Takahiro</creatorcontrib><creatorcontrib>Kojima, Takahiro</creatorcontrib><creatorcontrib>Inoue, Takahiro</creatorcontrib><creatorcontrib>Mizowaki, Takashi</creatorcontrib><creatorcontrib>Sugimoto, Mikio</creatorcontrib><creatorcontrib>Kitamura, Hiroshi</creatorcontrib><creatorcontrib>Kamoto, Toshiyuki</creatorcontrib><creatorcontrib>Nishiyama, Hiroyuki</creatorcontrib><creatorcontrib>Habuchi, Tomonori</creatorcontrib><creatorcontrib>Saito, Toshihiro</creatorcontrib><creatorcontrib>Yoshimura, Koji</creatorcontrib><creatorcontrib>Takahashi, Atsushi</creatorcontrib><creatorcontrib>Shimazui, Toru</creatorcontrib><creatorcontrib>Goto, Takayuki</creatorcontrib><creatorcontrib>Hashimoto, Yasuhiro</creatorcontrib><creatorcontrib>Nagumo, Yoshiyuki</creatorcontrib><creatorcontrib>Yasumoto, Hiroaki</creatorcontrib><creatorcontrib>Mitsuzuka, Koji</creatorcontrib><creatorcontrib>Ito, Akihiro</creatorcontrib><creatorcontrib>Matsumoto, Hiroaki</creatorcontrib><creatorcontrib>Sugiyama, Takayuki</creatorcontrib><creatorcontrib>Miyake, Hideaki</creatorcontrib><creatorcontrib>Kuroiwa, Kentaro</creatorcontrib><creatorcontrib>Tsuchiya, Norihiko</creatorcontrib><creatorcontrib>Fukuta, Fumimasa</creatorcontrib><creatorcontrib>Morizane, Shuichi</creatorcontrib><creatorcontrib>Sato, Hiromi</creatorcontrib><creatorcontrib>Saito, Takuro</creatorcontrib><creatorcontrib>Shinohara, Nobuo</creatorcontrib><creatorcontrib>Enokida, Hideki</creatorcontrib><creatorcontrib>Yonemori, Masaya</creatorcontrib><creatorcontrib>Japanese Urological Oncology Group</creatorcontrib><creatorcontrib>the Japanese Urological Oncology Group</creatorcontrib><title>Cancer‐specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy</title><title>International journal of urology</title><addtitle>Int J Urol</addtitle><description>Objective
This study aimed to assess survival outcomes in older patients with de novo metastatic prostate cancer who initially received androgen deprivation therapy.
Methods
The retrospective multicenter study included 2784 men with metastatic prostate cancer who were treated with androgen deprivation therapy between 2008 and 2017. Patients were classified into <75, 75–79, and ≥80 age groups. Propensity score matching was conducted to assess the cancer‐specific survival of the groups. The 5‐year net overall survival of each group was derived to evaluate relative survival compared with the general population using the Pohar–Perme estimator and the 2019 Japan Life Table.
Results
During the follow‐up (median, 34 months), 1014 patients died, of which 807 died from metastatic prostate cancer progression. Compared with the <75 group, the cancer‐specific survival of the 75–79 group was similar (hazard ratio 1.07; 95% confidence interval 0.84–1.37; P = 0.580), whereas that of the ≥80 group was significantly worse (hazard ratio 1.41; 95% confidence interval 1.10–1.80; P = 0.006). The 5‐year net overall survival of the <75, 75–79, and ≥80 age groups were 0.678, 0761, and 0.718, respectively. The 5‐year net overall survival of patients aged ≥80 years with low‐ and high‐volume disease were 0.893 and 0.586, respectively, which was comparable with those in patients aged <75 years (0.872 and 0.586, respectively).
Conclusions
Older metastatic prostate cancer patients aged ≥80 years had poorer cancer‐specific survival compared with younger patients. Conversely, 5‐year net overall survival in older patients aged ≥80 years was comparable with that in younger patients aged <75 years.</description><subject>Age groups</subject><subject>androgen deprivation therapy</subject><subject>Androgens</subject><subject>cancer‐specific survival</subject><subject>Confidence intervals</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>metastatic</subject><subject>older</subject><subject>Prostate cancer</subject><subject>Survival</subject><issn>0919-8172</issn><issn>1442-2042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kc1u1DAUhS0EokNhwQsgS2xgkdY_iRMv0Yifokps6Npy4hvqUcYOtjPV7PoILHk-noTbprBAwhtb9nfPub6HkJecnXFc5363nPFay-4R2fC6FpVgtXhMNkxzXXW8FSfkWc47xrgUvHtKTmSjuNRSbcjPrQ0DpF-3P_IMgx_9QG1wNECh8QDJThPNSzr4g52oDzRODhKdbfEQSqY3vlxTBzTEQ6R7KDYXfBronOLdCehwr46VvnjUOtKSAO_dWolOKX6DgBJzQoviY6DlGm3n43PyZLRThhcP-ym5-vD-6_ZTdfnl48X23WU1SNl2lXC943WndK9Z0yil2gZ6V3e9dkPrxChVw0Copmt6qbgeda2Udq3rmGutwxmckjerLvb8fYFczN7nAabJBohLNkK1jCnBhUT09T_oLi4pYHdGtEJIVYuOI_V2pQYcQk4wGvzb3qaj4czcxWUwLnMfF7KvHhSXfg_uL_knHwTOV-DGT3D8v5K5-Hy1Sv4GKtmiUA</recordid><startdate>202210</startdate><enddate>202210</enddate><creator>Narita, Shintaro</creator><creator>Terada, Naoki</creator><creator>Nomura, Kyoko</creator><creator>Sakamoto, Shinichi</creator><creator>Hatakeyama, Shingo</creator><creator>Kato, Takuma</creator><creator>Matsui, Yoshiyuki</creator><creator>Inokuchi, Junichi</creator><creator>Yokomizo, Akira</creator><creator>Tabata, Ken‐ichi</creator><creator>Shiota, Masaki</creator><creator>Kimura, Takahiro</creator><creator>Kojima, Takahiro</creator><creator>Inoue, Takahiro</creator><creator>Mizowaki, Takashi</creator><creator>Sugimoto, Mikio</creator><creator>Kitamura, Hiroshi</creator><creator>Kamoto, Toshiyuki</creator><creator>Nishiyama, Hiroyuki</creator><creator>Habuchi, Tomonori</creator><creator>Saito, Toshihiro</creator><creator>Yoshimura, Koji</creator><creator>Takahashi, Atsushi</creator><creator>Shimazui, Toru</creator><creator>Goto, Takayuki</creator><creator>Hashimoto, Yasuhiro</creator><creator>Nagumo, Yoshiyuki</creator><creator>Yasumoto, Hiroaki</creator><creator>Mitsuzuka, Koji</creator><creator>Ito, Akihiro</creator><creator>Matsumoto, Hiroaki</creator><creator>Sugiyama, Takayuki</creator><creator>Miyake, Hideaki</creator><creator>Kuroiwa, Kentaro</creator><creator>Tsuchiya, Norihiko</creator><creator>Fukuta, Fumimasa</creator><creator>Morizane, Shuichi</creator><creator>Sato, Hiromi</creator><creator>Saito, Takuro</creator><creator>Shinohara, Nobuo</creator><creator>Enokida, Hideki</creator><creator>Yonemori, Masaya</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5673-1553</orcidid><orcidid>https://orcid.org/0000-0001-8586-784X</orcidid><orcidid>https://orcid.org/0000-0002-8135-8746</orcidid><orcidid>https://orcid.org/0000-0003-2988-1860</orcidid></search><sort><creationdate>202210</creationdate><title>Cancer‐specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy</title><author>Narita, Shintaro ; Terada, Naoki ; Nomura, Kyoko ; Sakamoto, Shinichi ; Hatakeyama, Shingo ; Kato, Takuma ; Matsui, Yoshiyuki ; Inokuchi, Junichi ; Yokomizo, Akira ; Tabata, Ken‐ichi ; Shiota, Masaki ; Kimura, Takahiro ; Kojima, Takahiro ; Inoue, Takahiro ; Mizowaki, Takashi ; Sugimoto, Mikio ; Kitamura, Hiroshi ; Kamoto, Toshiyuki ; Nishiyama, Hiroyuki ; Habuchi, Tomonori ; Saito, Toshihiro ; Yoshimura, Koji ; Takahashi, Atsushi ; Shimazui, Toru ; Goto, Takayuki ; Hashimoto, Yasuhiro ; Nagumo, Yoshiyuki ; Yasumoto, Hiroaki ; Mitsuzuka, Koji ; Ito, Akihiro ; Matsumoto, Hiroaki ; Sugiyama, Takayuki ; Miyake, Hideaki ; Kuroiwa, Kentaro ; Tsuchiya, Norihiko ; Fukuta, Fumimasa ; Morizane, Shuichi ; Sato, Hiromi ; Saito, Takuro ; Shinohara, Nobuo ; Enokida, Hideki ; Yonemori, Masaya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3378-2dbd14869b905566675ebd48b9dc7d2f3650e26585b3619f94669d7d80d7ad393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Age groups</topic><topic>androgen deprivation therapy</topic><topic>Androgens</topic><topic>cancer‐specific survival</topic><topic>Confidence intervals</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>metastatic</topic><topic>older</topic><topic>Prostate cancer</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Narita, Shintaro</creatorcontrib><creatorcontrib>Terada, Naoki</creatorcontrib><creatorcontrib>Nomura, Kyoko</creatorcontrib><creatorcontrib>Sakamoto, Shinichi</creatorcontrib><creatorcontrib>Hatakeyama, Shingo</creatorcontrib><creatorcontrib>Kato, Takuma</creatorcontrib><creatorcontrib>Matsui, Yoshiyuki</creatorcontrib><creatorcontrib>Inokuchi, Junichi</creatorcontrib><creatorcontrib>Yokomizo, Akira</creatorcontrib><creatorcontrib>Tabata, Ken‐ichi</creatorcontrib><creatorcontrib>Shiota, Masaki</creatorcontrib><creatorcontrib>Kimura, Takahiro</creatorcontrib><creatorcontrib>Kojima, Takahiro</creatorcontrib><creatorcontrib>Inoue, Takahiro</creatorcontrib><creatorcontrib>Mizowaki, Takashi</creatorcontrib><creatorcontrib>Sugimoto, Mikio</creatorcontrib><creatorcontrib>Kitamura, Hiroshi</creatorcontrib><creatorcontrib>Kamoto, Toshiyuki</creatorcontrib><creatorcontrib>Nishiyama, Hiroyuki</creatorcontrib><creatorcontrib>Habuchi, Tomonori</creatorcontrib><creatorcontrib>Saito, Toshihiro</creatorcontrib><creatorcontrib>Yoshimura, Koji</creatorcontrib><creatorcontrib>Takahashi, Atsushi</creatorcontrib><creatorcontrib>Shimazui, Toru</creatorcontrib><creatorcontrib>Goto, Takayuki</creatorcontrib><creatorcontrib>Hashimoto, Yasuhiro</creatorcontrib><creatorcontrib>Nagumo, Yoshiyuki</creatorcontrib><creatorcontrib>Yasumoto, Hiroaki</creatorcontrib><creatorcontrib>Mitsuzuka, Koji</creatorcontrib><creatorcontrib>Ito, Akihiro</creatorcontrib><creatorcontrib>Matsumoto, Hiroaki</creatorcontrib><creatorcontrib>Sugiyama, Takayuki</creatorcontrib><creatorcontrib>Miyake, Hideaki</creatorcontrib><creatorcontrib>Kuroiwa, Kentaro</creatorcontrib><creatorcontrib>Tsuchiya, Norihiko</creatorcontrib><creatorcontrib>Fukuta, Fumimasa</creatorcontrib><creatorcontrib>Morizane, Shuichi</creatorcontrib><creatorcontrib>Sato, Hiromi</creatorcontrib><creatorcontrib>Saito, Takuro</creatorcontrib><creatorcontrib>Shinohara, Nobuo</creatorcontrib><creatorcontrib>Enokida, Hideki</creatorcontrib><creatorcontrib>Yonemori, Masaya</creatorcontrib><creatorcontrib>Japanese Urological Oncology Group</creatorcontrib><creatorcontrib>the Japanese Urological Oncology Group</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Narita, Shintaro</au><au>Terada, Naoki</au><au>Nomura, Kyoko</au><au>Sakamoto, Shinichi</au><au>Hatakeyama, Shingo</au><au>Kato, Takuma</au><au>Matsui, Yoshiyuki</au><au>Inokuchi, Junichi</au><au>Yokomizo, Akira</au><au>Tabata, Ken‐ichi</au><au>Shiota, Masaki</au><au>Kimura, Takahiro</au><au>Kojima, Takahiro</au><au>Inoue, Takahiro</au><au>Mizowaki, Takashi</au><au>Sugimoto, Mikio</au><au>Kitamura, Hiroshi</au><au>Kamoto, Toshiyuki</au><au>Nishiyama, Hiroyuki</au><au>Habuchi, Tomonori</au><au>Saito, Toshihiro</au><au>Yoshimura, Koji</au><au>Takahashi, Atsushi</au><au>Shimazui, Toru</au><au>Goto, Takayuki</au><au>Hashimoto, Yasuhiro</au><au>Nagumo, Yoshiyuki</au><au>Yasumoto, Hiroaki</au><au>Mitsuzuka, Koji</au><au>Ito, Akihiro</au><au>Matsumoto, Hiroaki</au><au>Sugiyama, Takayuki</au><au>Miyake, Hideaki</au><au>Kuroiwa, Kentaro</au><au>Tsuchiya, Norihiko</au><au>Fukuta, Fumimasa</au><au>Morizane, Shuichi</au><au>Sato, Hiromi</au><au>Saito, Takuro</au><au>Shinohara, Nobuo</au><au>Enokida, Hideki</au><au>Yonemori, Masaya</au><aucorp>Japanese Urological Oncology Group</aucorp><aucorp>the Japanese Urological Oncology Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cancer‐specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy</atitle><jtitle>International journal of urology</jtitle><addtitle>Int J Urol</addtitle><date>2022-10</date><risdate>2022</risdate><volume>29</volume><issue>10</issue><spage>1147</spage><epage>1154</epage><pages>1147-1154</pages><issn>0919-8172</issn><eissn>1442-2042</eissn><abstract>Objective
This study aimed to assess survival outcomes in older patients with de novo metastatic prostate cancer who initially received androgen deprivation therapy.
Methods
The retrospective multicenter study included 2784 men with metastatic prostate cancer who were treated with androgen deprivation therapy between 2008 and 2017. Patients were classified into <75, 75–79, and ≥80 age groups. Propensity score matching was conducted to assess the cancer‐specific survival of the groups. The 5‐year net overall survival of each group was derived to evaluate relative survival compared with the general population using the Pohar–Perme estimator and the 2019 Japan Life Table.
Results
During the follow‐up (median, 34 months), 1014 patients died, of which 807 died from metastatic prostate cancer progression. Compared with the <75 group, the cancer‐specific survival of the 75–79 group was similar (hazard ratio 1.07; 95% confidence interval 0.84–1.37; P = 0.580), whereas that of the ≥80 group was significantly worse (hazard ratio 1.41; 95% confidence interval 1.10–1.80; P = 0.006). The 5‐year net overall survival of the <75, 75–79, and ≥80 age groups were 0.678, 0761, and 0.718, respectively. The 5‐year net overall survival of patients aged ≥80 years with low‐ and high‐volume disease were 0.893 and 0.586, respectively, which was comparable with those in patients aged <75 years (0.872 and 0.586, respectively).
Conclusions
Older metastatic prostate cancer patients aged ≥80 years had poorer cancer‐specific survival compared with younger patients. Conversely, 5‐year net overall survival in older patients aged ≥80 years was comparable with that in younger patients aged <75 years.</abstract><cop>Australia</cop><pub>Wiley Subscription Services, Inc</pub><pmid>35613936</pmid><doi>10.1111/iju.14938</doi><tpages>1154</tpages><orcidid>https://orcid.org/0000-0002-5673-1553</orcidid><orcidid>https://orcid.org/0000-0001-8586-784X</orcidid><orcidid>https://orcid.org/0000-0002-8135-8746</orcidid><orcidid>https://orcid.org/0000-0003-2988-1860</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0919-8172 |
| ispartof | International journal of urology, 2022-10, Vol.29 (10), p.1147-1154 |
| issn | 0919-8172 1442-2042 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2670062123 |
| source | Wiley-Blackwell Journals |
| subjects | Age groups androgen deprivation therapy Androgens cancer‐specific survival Confidence intervals Metastases Metastasis metastatic older Prostate cancer Survival |
| title | Cancer‐specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T04%3A53%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cancer%E2%80%90specific%20and%20net%20overall%20survival%20in%20older%20patients%20with%20de%20novo%20metastatic%20prostate%20cancer%20initially%20treated%20with%20androgen%20deprivation%20therapy&rft.jtitle=International%20journal%20of%20urology&rft.au=Narita,%20Shintaro&rft.aucorp=Japanese%20Urological%20Oncology%20Group&rft.date=2022-10&rft.volume=29&rft.issue=10&rft.spage=1147&rft.epage=1154&rft.pages=1147-1154&rft.issn=0919-8172&rft.eissn=1442-2042&rft_id=info:doi/10.1111/iju.14938&rft_dat=%3Cproquest_cross%3E2722364281%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2722364281&rft_id=info:pmid/35613936&rfr_iscdi=true |